Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Completed · Phase 2
Conditions studied: Lymphoma
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: This phase II trial is studying how well giving filgrastim together with chemotherapy and peripheral stem cell transplant works in treating patients with Hodgkin's lymphoma or non-Hodgkin's lymphoma.
Key facts
- Study ID
- NCT00005985
- Run by
- Masonic Cancer Center, University of Minnesota
- People needed
- 213
- Starts
- 2000-08-01
- Expected to finish
- 2007-02-01
- Last updated by the study team
- 2017-11-29
Who can join
Age: any, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Minnesota Cancer Center — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.